This invention provides novel salt and crystalline forms thereof of (-)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-- oxadiazol-2-yl}amino)-methyl]-2H-chromen-2-one. The compounds are 5-LO inhibitors and are useful for treatment of conditions such as asthma, allergic rhinitis, COPD, and atherosclerosis.
Claims What is claimed is: 1. Crystalline p-toluenesulfonic acid salt of (-)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-- oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one characterized by having an XRPD pattern obtained using CuK.alpha. radiation containing at least one d-spacing selected from 17.77, 8.90 and 5.17. 2. Crystalline p-toluenesulfonic acid salt of (-)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-- oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one characterized by having at least one chemical shift value obtained by solid-state carbon-13 CPMAS NMR selected from the group consisting of 48.5, 124.1, 152.4, 28.4, 141.3, 162.1, 74.8, 154.4 and 164.5 parts per million. 3. Crystalline p-toluenesulfonic acid salt of (-)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-- oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one characterized by having at least two chemical shift values obtained by solid-state carbon-13 CPMAS NMR selected from the group consisting of 48.5, 124.1, 152.4, 28.4, 141.3, 162.1, 74.8, 154.4 and 164.5 parts per million. 4. Crystalline p-toluenesulfonic acid salt of (-)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-- oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one characterized by having at least one chemical shift value obtained by solid-state fluorine-19 CPMAS NMR selected from the group consisting of -50.2, -75.6 and -101.3. 5. Crystalline p-toluenesulfonic acid salt of (-)4-(4-fluorophenyl)-7-[({5-[1-hydroxy-1-(trifluoromethyl)propyl]-1,3,4-- oxadiazol-2-yl}amino)methyl]-2H-chromen-2-one characterized by having at least two chemical shift values obtained by solid-state fluorine-19 CPMAS NMR selected from the group consisting of -50.2, -75.6 and -101.3. 6. A pharmaceutical composition comprising a crystalline p-toluenesulfonic acid salt selected from the group consisting of: (a) a salt characterized by having at least one chemical shift value obtained by solid-state carbon-13 CPMAS NMR selected from the group consisting of 48.5, 124.1, 152.4, 28.4, 141.3, 162.1, 74.8, 154.4 and 164.5 parts per million; (b) a salt characterized by having at least two chemical shift values obtained by solid-state carbon-13 CPMAS NMR selected from the group consisting of 48.5, 124.1, 152.4, 28.4, 141.3, 162.1, 74.8, 154.4 and 164.5 parts per million; (c) a salt characterized by having at least one chemical shift value obtained by solid-state fluorine-19 CPMAS NMR selected from the group consisting of -50.2, -75.6 and -101.3; and (d) a salt characterized by having at least two chemical shift values obtained by solid-state fluorine-19 CPMAS NMR selected from the group consisting of -50.2, -75.6 and -101.3; and a pharmaceutically acceptable carrier. 